{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:35:09Z","timestamp":1791167709806,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":2607,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Televie","award":["FC84766"],"award-info":[{"award-number":["FC84766"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1093\/annonc\/mds057","type":"journal-article","created":{"date-parts":[[2012,4,4]],"date-time":"2012-04-04T05:35:04Z","timestamp":1333517704000},"page":"2663-2670","source":"Crossref","is-referenced-by-count":117,"title":["Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers"],"prefix":"10.1016","volume":"23","author":[{"given":"E.","family":"Seront","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rottey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Sautois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.A.","family":"D'Hondt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Verschaeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-L.","family":"Canon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dopchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Vandenbulcke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Whenham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Goeminne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Clausse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Verhoeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Glorieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Branders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Dupont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Schoonjans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Feron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-P.","family":"Machiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mds057_bb0010","series-title":"Cancer Facts & Figures","author":"American Cancer Society","year":"2011"},{"key":"10.1093\/annonc\/mds057_bb0015","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","article-title":"Long term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome of therapy","volume":"17","author":"Bajorin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds057_bb0020","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1200\/JCO.1997.15.7.2564","article-title":"Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study","volume":"15","author":"Saxman","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds057_bb0025","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds057_bb0030","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","article-title":"Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract","volume":"27","author":"Bellmunt","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds057_bb0035","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/1535-7163.MCT-07-2408","article-title":"Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies","volume":"7","author":"Garcia","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mds057_bb0040","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/carcin\/bgp258","article-title":"Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk","volume":"30","author":"Chen","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1093\/annonc\/mds057_bb0045","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/sj.bjc.6690439","article-title":"Somatic mutation of PTEN in bladder carcinoma","volume":"80","author":"Aveyard","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mds057_bb0050","doi-asserted-by":"crossref","first-page":"7564","DOI":"10.1073\/pnas.0702507104","article-title":"Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity","volume":"104","author":"Saal","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mds057_bb0055","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10555-009-9198-3","article-title":"Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer","volume":"28","author":"Knowles","year":"2009","journal-title":"Cancer Metastasis Rev"},{"key":"10.1093\/annonc\/mds057_bb0060","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1158\/1078-0432.CCR-09-0898","article-title":"Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer","volume":"15","author":"Platt","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds057_bb0065","doi-asserted-by":"crossref","first-page":"8256","DOI":"10.1158\/0008-5472.CAN-09-1689","article-title":"Activation of the PI3K\/Akt pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models","volume":"69","author":"Qian","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mds057_bb0070","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1038\/sj.onc.1206285","article-title":"VEGF receptor expression and signalling in human bladder tumors","volume":"22","author":"Wu","year":"2003","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mds057_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1078-1439(03)00015-2","article-title":"The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression","volume":"22","author":"Yang","year":"2004","journal-title":"Urol Oncol"},{"key":"10.1093\/annonc\/mds057_bb0080","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds057_bb0085","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds057_bb0090","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds057_bb0095","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.urology.2008.09.070","article-title":"Rapamycin inhibits in vitro growth release of angiogenetic factors in human bladder cancer","volume":"73","author":"Fechner","year":"2009","journal-title":"Urology"},{"key":"10.1093\/annonc\/mds057_bb0100","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.4161\/cbt.8.24.9987","article-title":"Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer","volume":"8","author":"Mansure","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1093\/annonc\/mds057_bb0105","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1158\/1078-0432.CCR-09-3202","article-title":"Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells","volume":"17","author":"Chiong","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds057_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1093\/annonc\/mds057_bb0115","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","article-title":"Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens","volume":"28","author":"Bellmunt","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds057_bb0120","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3816\/CGC.2008.n.006","article-title":"Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum based chemotherapy","volume":"6","author":"Beer","year":"2008","journal-title":"Clin Genitourin Cancer"},{"key":"10.1093\/annonc\/mds057_bb0125","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.urolonc.2004.11.008","article-title":"A phase II study of oxaliplatin in urothelial cancer","volume":"23","author":"Winquist","year":"2005","journal-title":"Urol Oncol"},{"key":"10.1093\/annonc\/mds057_bb0130","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1023\/A:1006159525793","article-title":"Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial","volume":"16","author":"Witte","year":"1998","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mds057_bb0135","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0959-8049(98)00030-6","article-title":"A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer","volume":"34","author":"Lorusso","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mds057_bb0140","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2002.20.4.937","article-title":"Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer","volume":"20","author":"Vaughn","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds057_bb0145","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1200\/JCO.1997.15.5.1853","article-title":"Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma","volume":"15","author":"McCaffrey","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds057_bb0150","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/cncr.22839","article-title":"Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group","volume":"110","author":"Dreicer","year":"2007","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds057_bb0155","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1200\/JCO.2005.03.6699","article-title":"Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium","volume":"24","author":"Sweeney","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds057_bb0160","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/cncr.24337","article-title":"A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma","volume":"115","author":"Wulfing","year":"2009","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds057_bb0165","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.e16030","article-title":"Phase II study of aflibercept (VEGF-Trap) in patients (pts) with recurrent or metastatic transitional cell carcinoma (TCC) of the urothelium: A California Cancer Consortium trial","volume":"27","author":"Twardowski","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds057_bb0170","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1002\/cncr.24467","article-title":"Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group","volume":"115","author":"Dreicer","year":"2009","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds057_bb0175","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1200\/JCO.2009.25.3922","article-title":"Phase II study of sunitinib in patients with metastatic urothelial cancer","volume":"28","author":"Gallagher","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds057_bb0180","unstructured":"Necchi A, Nicolai N, Guglielmi A, et al. Phase II study of pazopanib monotherapy for patients with relapsed\/refractory urothelial cancer.. Presented at the 35th European Society for Medical Oncology (ESMO) Congress. Milan, Italy, October 8\u201312, 2010"},{"key":"10.1093\/annonc\/mds057_bb0185","first-page":"15s","article-title":"Final results of a phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium","volume":"29","author":"Milowsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds057_bb0190","first-page":"7s","article-title":"Phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium","volume":"29","author":"Milowsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds057_bb0195","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1111\/j.1349-7006.2008.00961.x","article-title":"Angiopoietin-1 alters tumor growth by stabilizing blood vessels or by promoting angiogenesis","volume":"99","author":"Satoh","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1093\/annonc\/mds057_bb0200","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1464-410X.2005.05358.x","article-title":"Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer","volume":"95","author":"Oka","year":"2005","journal-title":"BJU Int"},{"key":"10.1093\/annonc\/mds057_bb0205","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1523\/JNEUROSCI.5597-09.2010","article-title":"The angiogenic factor angiopoietin-1 is a proneurogenic peptide on subventricular zone stem\/progenitor cells","volume":"30","author":"Rosa","year":"2010","journal-title":"J Neurosci"},{"key":"10.1093\/annonc\/mds057_bb0210","first-page":"524","article-title":"Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin","volume":"7","author":"Takahashi","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds057_bb0215","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1073\/pnas.171076798","article-title":"Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR","volume":"98","author":"Neshat","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mds057_bb0220","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3816\/CGC.2007.n.020","article-title":"Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma","volume":"5","author":"Cho","year":"2007","journal-title":"Clin Genitourin Cancer"},{"key":"10.1093\/annonc\/mds057_bb0225","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1200\/JCO.2010.34.1578","article-title":"Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC clinical trial group","volume":"29","author":"Oza","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds057_bb0230","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2008.21.3033","article-title":"Randomized phase II study comparing two schedules of everolimus in patients with recurrent\/metastatic breast cancer: NCIC Clinical Trials Group IND.163","volume":"27","author":"Ellard","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds057_bb0235","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1038\/onc.2011.42","article-title":"PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs","volume":"30","author":"Weigelt","year":"2011","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mds057_bb0240","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1371\/journal.pmed.0050008","article-title":"Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma","volume":"5","author":"Cloughesy","year":"2008","journal-title":"PLoS Med"},{"key":"10.1093\/annonc\/mds057_bb0245","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","article-title":"Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism","volume":"26","author":"Wan","year":"2007","journal-title":"Oncogene"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419379499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419379499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/10\/2663\/13786293\/mds057.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:25:36Z","timestamp":1624519536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419379499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0923753419379499"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds057","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}